Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Captopril
Drug ID BADD_D00354
Description Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Indications and Usage For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Marketing Status approved
ATC Code C09AA01
DrugBank ID DB01197
KEGG ID D00251
MeSH ID D002216
PubChem ID 44093
TTD Drug ID D0I0EG
NDC Product Code 27241-162; 31722-141; 31722-142; 0143-1171; 63629-8728; 69292-526; 53296-0031; 31722-144; 0143-1174; 60687-304; 63629-1338; 63629-8730; 0781-8061; 0904-7105; 63629-8729; 70518-3307; 71335-1918; 51552-1072; 51927-0137; 27241-160; 27241-161; 43547-363; 63629-8727; 69292-522; 71335-0826; 0781-8052; 53069-0150; 31722-143; 27241-163; 51407-601; 51407-602; 51407-603; 43547-366; 55289-344; 0781-8080; 55488-0600; 43547-364; 0781-8075; 0143-1172; 0143-1173; 43547-365; 50090-5964; 51407-600; 60687-315; 69292-524; 69292-528; 0904-7106
UNII 9G64RSX1XD
Synonyms Captopril | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | Lopirin | SQ-14,534 | SQ 14,534 | SQ14,534 | SQ-14534 | SQ 14534 | SQ14534 | Capoten | SQ-14,225 | SQ 14,225 | SQ14,225 | SQ-14225 | SQ 14225 | SQ14225
Chemical Information
Molecular Formula C9H15NO3S
CAS Registry Number 62571-86-2
SMILES CC(CS)C(=O)N1CCCC1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholestasis09.01.01.001---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Cough22.02.03.0010.000488%
Cutis laxa15.06.01.007; 23.03.02.0090.000488%-
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.0070.000732%
Death08.04.01.001--
Dehydration14.05.05.0010.000975%
Depression19.15.01.001--
Dermatitis23.03.04.002---
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.000975%
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.001073%-
Drug hypersensitivity10.01.01.001---
Drug interaction08.06.03.001---
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.000975%
Dyspnoea02.11.05.003; 22.02.01.0040.003414%
Electrolyte imbalance14.05.01.0020.000488%-
Eosinophilia01.02.04.001--
Eosinophilic pneumonia01.02.04.003; 22.01.01.004---
Erythema23.03.06.0010.001073%-
Erythema multiforme10.01.03.015; 23.03.01.003--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene